<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465878</url>
  </required_header>
  <id_info>
    <org_study_id>16695</org_study_id>
    <secondary_id>I8B-MC-ITSA</secondary_id>
    <secondary_id>2017-003220-78</secondary_id>
    <nct_id>NCT03465878</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 in Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in
      participants with type 1 diabetes mellitus.

      There are 2 parts to this study. Part A is investigating how the body processes LY900014 and
      the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study
      treatment is given by subcutaneous injection. Part B of the study is investigating how the
      body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin
      lispro (Humalog) when study treatment is given by continuous subcutaneous insulin infusion
      (CSII) pump.

      Screening is required within 28 days prior to the start of the study. For each participant,
      the study will last about 40 days in each part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part</measure>
    <time_frame>Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose</time_frame>
    <description>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part</measure>
    <time_frame>-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose</time_frame>
    <description>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LY900014-Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog (Insulin Lispro)-Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014-Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog (Insulin Lispro)-Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY900014-Part A</arm_group_label>
    <arm_group_label>LY900014-Part B</arm_group_label>
    <other_name>Ultra-Rapid Lispro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>Humalog (Insulin Lispro)-Part A</arm_group_label>
    <arm_group_label>Humalog (Insulin Lispro)-Part B</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at
             least 1 year

          -  Have a glycated hemoglobin (HbA1c) less than (&lt;)10.0 percent (%)

        Exclusion Criteria:

          -  Receiving any oral or injectable medication intended for the treatment of diabetes
             mellitus other than insulins in the 12 months prior to screening

          -  More than one episode of severe hypoglycaemia in the last 6 months

          -  Presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or
             gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease,
             uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency

          -  Have obvious clinical signs or symptoms of liver disease

          -  Have a history of renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LMC Endocrinology Centres Ltd.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus auf der Bult</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/type-1-diabetes/ITSA#?postal=</url>
    <description>A Study of LY900014 in Participants With Type 1 Diabetes Mellitus</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>June 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2020</results_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03465878/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03465878/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants (pts) who completed Part A but discontinued before the beginning of Part B were replaced by newly enrolled participants in Part B.</recruitment_details>
      <pre_assignment_details>Two period crossover study, with a minimum of 22 days washout period between each period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1-Part A</title>
          <description>Participants received either single 0.2 units per kilogram (U/kg) of body weight subcutaneous (SC) bolus injection of 100 units per milliliter (U/mL) LY900014 or Humalog.
Period 1: LY900014 Period 2: Humalog</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2-Part A</title>
          <description>Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014 or Humalog.
Period 1: Humalog Period 2: LY900014</description>
        </group>
        <group group_id="P3">
          <title>Sequence 1-Part B</title>
          <description>Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of 100 U/mL LY900014 or Humalog delivered using the continuous subcutaneous insulin infusion (CSII) pump.
Period 1: LY900014 Period 2: Humalog</description>
        </group>
        <group group_id="P4">
          <title>Sequence 2-Part B</title>
          <description>Participants received either single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of 100 U/mL LY900014 or Humalog with delivered using the CSII pump.
Period 1: Humalog Period 2: LY900014</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1-Part A First Intervention Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Children (2-11 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adolescents (12-17 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adults (18-64 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period2-Part A Second Intervention Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Children (2-11 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adolescents (12-17 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adults (18-64 Years)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1-Part B First Intervention Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This period is for Part B group.</participants>
                <participants group_id="P2" count="0">This period is for Part B group.</participants>
                <participants group_id="P3" count="20">25 pts from Part A were re-randomized to Part B, 14 new pts were randomized in Part B.</participants>
                <participants group_id="P4" count="19">25 pts from Part A were re-randomized to Part B, 14 new pts were randomized in Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Children (2-11 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adolescents (12-17 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adults (18-64 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period2-Part B Second Intervention Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Children (2-11 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adolescents (12-17 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Adults (18-64 Years)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All newly randomized participants of Part A and Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014 or Humalog.</description>
        </group>
        <group group_id="B2">
          <title>Part B</title>
          <description>Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus infusion of either 100 U/mL LY900014 or Humalog delivered using the CSII pump.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="15.1"/>
                    <measurement group_id="B2" value="23.2" spread="11.1"/>
                    <measurement group_id="B3" value="21.2" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Children (2-11 Years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adolescents (12-17 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adults (18-64 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part</title>
        <description>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.</description>
        <time_frame>Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Children-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.</description>
          </group>
          <group group_id="O2">
            <title>Children-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O3">
            <title>Adolescents-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.</description>
          </group>
          <group group_id="O4">
            <title>Adolescents-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O5">
            <title>Adults-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100U/mL LY900014.</description>
          </group>
          <group group_id="O6">
            <title>Adults-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O7">
            <title>Children-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O8">
            <title>Children-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
          <group group_id="O9">
            <title>Adolescents-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O10">
            <title>Adolescents-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
          <group group_id="O11">
            <title>Adults-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O12">
            <title>Adults-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part</title>
          <description>Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>Picomoles*hour/Liter (pmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="13"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="755" spread="15"/>
                    <measurement group_id="O2" value="754" spread="17"/>
                    <measurement group_id="O3" value="962" spread="17"/>
                    <measurement group_id="O4" value="908" spread="21"/>
                    <measurement group_id="O5" value="987" spread="20"/>
                    <measurement group_id="O6" value="975" spread="21"/>
                    <measurement group_id="O7" value="743" spread="17"/>
                    <measurement group_id="O8" value="714" spread="17"/>
                    <measurement group_id="O9" value="842" spread="20"/>
                    <measurement group_id="O10" value="866" spread="16"/>
                    <measurement group_id="O11" value="1100" spread="35"/>
                    <measurement group_id="O12" value="1070" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9813</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>0.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.918</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1638</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.976</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7623</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.933</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2952</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.962</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4052</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>0.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5314</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric least squares means</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.948</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part</title>
        <description>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.</description>
        <time_frame>-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable Glucodynamics data.</population>
        <group_list>
          <group group_id="O1">
            <title>Children-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.</description>
          </group>
          <group group_id="O2">
            <title>Children-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O3">
            <title>Adolescents-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.</description>
          </group>
          <group group_id="O4">
            <title>Adolescents-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O5">
            <title>Adults-LY900014-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100U/mL LY900014.</description>
          </group>
          <group group_id="O6">
            <title>Adults-Humalog-Part A</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
          </group>
          <group group_id="O7">
            <title>Children-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O8">
            <title>Children-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
          <group group_id="O9">
            <title>Adolescents-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O10">
            <title>Adolescents-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
          <group group_id="O11">
            <title>Adults-LY900014-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
          </group>
          <group group_id="O12">
            <title>Adults-Humalog-Part B</title>
            <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part</title>
          <description>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable Glucodynamics data.</population>
          <units>milligrams*hour per deciliter (mg*h/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="13"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384" spread="335"/>
                    <measurement group_id="O2" value="492" spread="270"/>
                    <measurement group_id="O3" value="577" spread="247"/>
                    <measurement group_id="O4" value="651" spread="238"/>
                    <measurement group_id="O5" value="372" spread="179"/>
                    <measurement group_id="O6" value="351" spread="240"/>
                    <measurement group_id="O7" value="602" spread="221"/>
                    <measurement group_id="O8" value="582" spread="254"/>
                    <measurement group_id="O9" value="614" spread="160"/>
                    <measurement group_id="O10" value="614" spread="163"/>
                    <measurement group_id="O11" value="343" spread="194"/>
                    <measurement group_id="O12" value="401" spread="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to Study Completion (Up to 20 Months)</time_frame>
      <desc>All randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Children-LY900014-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.</description>
        </group>
        <group group_id="E2">
          <title>Children-Humalog-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
        </group>
        <group group_id="E3">
          <title>Adolescents-LY900014-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL LY900014.</description>
        </group>
        <group group_id="E4">
          <title>Adolescents-Humalog-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
        </group>
        <group group_id="E5">
          <title>Adults-LY900014-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100U/mL LY900014.</description>
        </group>
        <group group_id="E6">
          <title>Adults-Humalog-Part A</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL Humalog.</description>
        </group>
        <group group_id="E7">
          <title>Children-LY900014-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
        </group>
        <group group_id="E8">
          <title>Children-Humalog-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
        </group>
        <group group_id="E9">
          <title>Adolescents-LY900014-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
        </group>
        <group group_id="E10">
          <title>Adolescents-Humalog-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
        </group>
        <group group_id="E11">
          <title>Adults-LY900014-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the CSII pump.</description>
        </group>
        <group group_id="E12">
          <title>Adults-Humalog-Part B</title>
          <description>Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acne pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lipohypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

